2018
DOI: 10.1002/ange.201805208
|View full text |Cite
|
Sign up to set email alerts
|

Solid‐Phase Thiol–Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist

Abstract: We report a new method herein coined SP‐CLipPA (solid‐phase cysteine lipidation of a peptide or amino acid) for the synthesis of mono‐S‐lipidated peptides. This technique utilizes thiol–ene chemistry for conjugation of a vinyl ester to a free thiol of a semiprotected, resin‐bound peptide. Advantages of SP‐CLipPA include: ease of handling, conversions of up to 91 %, by‐product removal by simple filtration, and a single purification step. Additionally, the desired lipidated products show high chromatographic sep… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
5
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 14 publications
(5 citation statements)
references
References 34 publications
0
5
0
Order By: Relevance
“…During the SPPS,the 4-monomethoxytrityl (Mmt)-protected Cys9 was installed into the peptide.A fter peptide assembly, the Mmt group in the resin-bound peptide precursor was selectively removed by treatment with 2% trifluoroacetic acid (TFA) cocktails to give afree thiol. [19] Thereleased thiol then reacted with palmitic anhydride to generate S-palm SLN 1.U nfortunately,t he crude peptide 1 was found to be insoluble,and no target product was detected in the reversedphase high-performance liquid chromatography (RP-HPLC) profile ( Figure 1b). We also examined other previously developed strategies [20] (such as the use of NMP/DMF cosolvents,microwave irradiation, pseudoproline,and O-acyl isopeptide,and the attachment of solubilizing tags on peptide side chains) to improve the synthetic efficiency.However,no significant improvement was observed by RP-HPLC (see Figure S1 in the Supporting Information), presumably owing to the strong hydrophobicity of 1.…”
Section: Resultsmentioning
confidence: 99%
“…During the SPPS,the 4-monomethoxytrityl (Mmt)-protected Cys9 was installed into the peptide.A fter peptide assembly, the Mmt group in the resin-bound peptide precursor was selectively removed by treatment with 2% trifluoroacetic acid (TFA) cocktails to give afree thiol. [19] Thereleased thiol then reacted with palmitic anhydride to generate S-palm SLN 1.U nfortunately,t he crude peptide 1 was found to be insoluble,and no target product was detected in the reversedphase high-performance liquid chromatography (RP-HPLC) profile ( Figure 1b). We also examined other previously developed strategies [20] (such as the use of NMP/DMF cosolvents,microwave irradiation, pseudoproline,and O-acyl isopeptide,and the attachment of solubilizing tags on peptide side chains) to improve the synthetic efficiency.However,no significant improvement was observed by RP-HPLC (see Figure S1 in the Supporting Information), presumably owing to the strong hydrophobicity of 1.…”
Section: Resultsmentioning
confidence: 99%
“…[15] We have previously used this peptide to demonstrate a solid-phase variant of CLipPA (SP-CLipPA). [16] S-lipidation with either vinyl palmitate or vinyl benzoate in the presence of either t-NonylSH or tBuSH gave excellent conversions (>95 %) to the desired lipopeptides 4b and 4c. On a multi-milligram scale, S-palmitoylated lipopeptide 4b was isolated in a 47 % yield, a substantial improvement to that reported previously.…”
Section: Resultsmentioning
confidence: 99%
“…Peptide sequence 4a is a potent antagonist of the calcitonin gene‐related peptide (CGRP) receptor used in the development of new migraine treatments . We have previously used this peptide to demonstrate a solid‐phase variant of CLipPA (SP‐CLipPA) . S ‐lipidation with either vinyl palmitate or vinyl benzoate in the presence of either t‐NonylSH or t BuSH gave excellent conversions (>95 %) to the desired lipopeptides 4b and 4c .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Encouraged by these reports and the recent progression of several polymyxins, including Spero’s SPR206, Qpex BioPharma’s QPX9003, , and MicuRx’s MRX8 to clinical trials, we focused on preparing polymyxin B analogues that contained unique lipids anchored by a novel 2-thioethyl ester linkage via the peptide backbone at the N-terminus, position 7, position 6, or the combination of several of these sites. The 2-thioethyl ester linkage can be introduced using thiol–ene-promoted S -lipidation (which we termed CLipPA: C ysteine Lip idation on a P eptide or A mino acid). CLipPA S-lipidation takes place via a radical-initiated thiol–ene reaction between the free thiol of a cysteine residue (or surrogate) and the terminal sp 2 carbon atom on a fatty acid vinyl ester. We chose to preserve the five cationic Dab residues based on the widely accepted mechanism of action studies; these cationic side-chain amino groups are essential to initiate disabling of lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria through electrostatic interactions, prior to the subsequent lipid tail insertion into the membrane. , …”
mentioning
confidence: 99%